{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:50:52Z","timestamp":1790542252093,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has lasted more than 2\u00a0years with over 260 million infections and 5 million deaths worldwide as of November 2021. To combat the virus, monoclonal antibodies blocking the virus binding to human receptor, the angiotensin converting enzyme 2 (ACE2), have been approved to treat the infected patients. Inactivated whole virus or the full-length virus spike encoding adenovirus or mRNA vaccines are being used to immunize the public. However, SARS-CoV-2 variants are emerging. These, to some extent, escape neutralization by the therapeutic antibodies and vaccine-induced immunity. Thus, breakthrough infections by SARS-CoV-2 variants have been reported in previously virus-infected or fully vaccinated individuals. The receptor binding domain (RBD) of the virus spike protein reacts with host ACE2, leading to the entry of the virus into the cell. It is also the major antigenic site of the virus, with more than 90% of broadly neutralizing antibodies from either infected patients or vaccinated individuals targeting the spike RBD. Therefore, mutations in the RBD region are effective ways for SARS-CoV-2 variants to gain infectivity and escape the immunity built up by the original vaccines or infections. In this review, we focus on the impact of RBD mutations in SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI) on ACE2 binding affinity and escape of serum antibody neutralization. We also provide protein structure models to show how the VOC and VOI RBD mutations affect ACE2 binding and allow escape of the virus from the therapeutic antibody, bamlanivimab.<\/jats:p>","DOI":"10.3389\/fimmu.2022.825256","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T09:40:01Z","timestamp":1643276401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity"],"prefix":"10.3389","volume":"13","author":[{"given":"Haolin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Kappler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Marrack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus From Patients With Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The Neutralizing Antibody, LY-CoV555, Protects Against SARS-CoV-2 Infection in Nonhuman Primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci Trans Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0827","article-title":"Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients With Covid-19","volume":"384","author":"Chen","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19","volume":"384","author":"Weinreich","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1860476","article-title":"Antibodies to Watch in 2021","volume":"13","author":"Kaplon","year":"2021","journal-title":"mAbs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.Cov2.S Vaccine Against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 Ncov-19) Covid-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01031-17","article-title":"Complexities of Viral Mutation Rates","volume":"92","author":"Peck Kayla","year":"2016","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","article-title":"Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant","volume":"183","author":"Yurkovetskiy","year":"2020","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/v13081642","article-title":"Emergence of E484K Mutation Following Bamlanivimab Monotherapy Among High-Risk Patients Infected With the Alpha Variant of SARS-CoV-2","volume":"13","author":"Peiffer-Smadja","year":"2021","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.cell.2021.03.027","article-title":"SARS-CoV-2 Evolution in an Immunocompromised Host Reveals Shared Neutralization Escape Mechanisms","volume":"184","author":"Clark","year":"2021","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00496-8","article-title":"The Basis of a More Contagious 501Y.V1 Variant of SARS-CoV-2","volume":"31","author":"Liu","year":"2021","journal-title":"Cell Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1919285","article-title":"501y.V2 and 501Y.V3 Variants of SARS-CoV-2 Lose Binding to Bamlanivimab In Vitro","volume":"13","author":"Liu","year":"2021","journal-title":"mAbs"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1101\/2021.08.25.457692","article-title":"The Lambda Variant of SARS-CoV-2 has a Better Chance Than the Delta Variant to Escape Vaccines","volume-title":"bioRxiv","author":"Liu","year":"2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e70658","DOI":"10.1101\/2021.05.18.444646","article-title":"Effects of Common Mutations in the SARS-CoV-2 Spike RBD and Its Ligand, the Human ACE2 Receptor on Binding Affinity and Kinetics","volume":"10","author":"Barton","year":"2021","journal-title":"eLife"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1038\/s41467-021-26401-w","article-title":"Molecular Insights Into Receptor Binding of Recent Emerging SARS-CoV-2 Variants","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 Neutralizing Antibody Structures Inform Therapeutic Strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 Breakthrough Infections in Vaccinated Health Care Workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c Mice for Testing Vaccine Efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.06.459005","article-title":"Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.09.011","article-title":"mRNA Vaccination of Naive and COVID-19-Recovered Individuals Elicits Potent Memory B Cells That Recognize SARS-CoV-2 Variants","volume":"54","author":"Sokal","year":"2021","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100255","article-title":"Complete Map of SARS-CoV-2 RBD Mutations That Escape the Monoclonal Antibody LY-CoV555 and Its Cocktail With LY-Cov016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y","article-title":"In Vivo Monoclonal Antibody Efficacy Against SARS-CoV-2 Variant Strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain That Escape Antibody Recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1101\/2021.07.07.21260122","article-title":"Viral Infection and Transmission in a Large, Well-Traced Outbreak Caused by the SARS-CoV-2 Delta Variant","volume-title":"medRxiv","author":"Li","year":"2021"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1101\/2021.08.12.456173","article-title":"Delta Spike P681R Mutation Enhances SARS-CoV-2 Fitness Over Alpha Variant","volume-title":"bioRxiv","author":"Liu","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","article-title":"SARS-CoV-2 Spike L452R Variant Evades Cellular Immunity and Increases Infectivity","volume":"29","author":"Motozono","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B35","article-title":"B.1.1.529 Escapes the Majority of SARS-CoV-2 Neutralizing Antibodies of Diverse Epitopes","volume-title":"bioRxiv","author":"Cao","year":"2021"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1101\/2021.12.07.21267432","article-title":"Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies","volume-title":"medRxiv","author":"Wilhelm","year":"2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.biochem.76.061705.090740","article-title":"Molecular Mechanisms of Antibody Somatic Hypermutation","volume":"76","author":"Di Noia","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.12.045","article-title":"Complement and Viral Pathogenesis","volume":"411","author":"Stoermer","year":"2011","journal-title":"Virology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T09:40:04Z","timestamp":1643276404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.825256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2022.825256"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.825256","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"article-number":"825256"}}